Table 4.
Clinical and pathologic characteristics of patients with either negative lymph nodes or no lymphadenectomy performed
| Characteristic | SLN Cohort (n=92) | LND Cohort (n=76) | P† |
|---|---|---|---|
| Age (years), mean (SD) | 66.0 (±8.6) | 66.6 (±12.2) | 0.69 |
| BMI (kg/m2), mean (SD) | 29.8 (±6.6) | 30.5 (±7.8) | 0.57 |
| FIGO grade 3, n (%) | 92 (100.0%) | 76 (100.0%) | -- |
| FIGO stage (2009), n (%) | 0.45 | ||
| I | 80 (87.0%) | 70 (92.1%) | |
| II | 7 (7.6%) | 2 (2.6%) | |
| III | 5 (5.4%) | 4 (5.3%) | |
| Myometrial invasion, n (%) | 0.01 | ||
| None | 49 (53.3%) | 25 (32.9%) | |
| <50% | 25 (27.2%) | 37 (48.7%) | |
| ≥50% | 18 (19.6%) | 14 (18.4%) | |
| LVSI, n (%) | 26 (28.3%) | 15 (19.7%) | 0.20 |
| Cervical stromal invasion, n (%) | 8 (8.7%) | 2 (2.6%) | 0.11 |
| Malignant peritoneal cytology, n (%)‡ | 12/89 (13.5%) | 9/67 (13.2%) | 0.96 |
| Pelvic LND, n (%) | 0.005 | ||
| No | 3 (3.3%) | 12 (15.8%) | |
| Yes | 89 (96.7%) | 64 (84.2%) | |
| Paraaortic LND, n (%) | <0.001 | ||
| No | 54 (58.7%) | 18 (23.7%) | |
| Yes | 38 (41.3%) | 58 (76.3%) | |
| Adjuvant therapy, n (%) | <0.001 | ||
| None | 9 (9.8%) | 20 (26.3%) | |
| IVRT | 7 (7.6%) | 27 (35.5%) | |
| EBRT ± IVRT | 1 (1.1%) | 1 (1.3%) | |
| Chemotherapy ± IVRT | 69 (75.0%) | 21 (27.6%) | |
| Chemotherapy and EBRT ± IVRT | 6 (6.5%) | 1 (1.3%) | |
| Unknown | 0 (0%) | 6 (7.9%) | |
SD=standard deviation, BMI=body mass index, LVSI=lymphovascular space invasion, LND=lymphadenectomy.
†
Comparisons between groups were evaluated using the two-sample t-test for age and BMI, and the chi-square or Fisher’s exact test for all other categorical characteristics.
‡
11 patients (3 in the SLN cohort and 8 in the LND cohort) with unknown peritoneal cytology sampling were ignored from the univariate analysis due to no peritoneal cytology sampling.